Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

Novo Nordisk agreed to pay up to $2 billion for ... early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

and now it looks like we'll have the next generation of these breakthrough weight loss and diabetes medicines on shelves by early next year. Less than five years on from when Novo Nordisk's ...

The dive in Novo Nordisk's stock price in March 2025 was primarily due to a pipeline setback. Earlier this month, the company reported achieving a 15.7% weight loss in obese and type 2 diabetes ...

In 2024, Novo Nordisk's Ozempic generated nearly $17 billion in sales and Wegovy brought in around $8 billion. Eli Lilly's Type 2 diabetes drug is Mounjaro and the weight-loss version is Zepbound.